Company / Operating Cash Flow per Share
Aquestive Therapeutics, Inc. Operating Cash Flow per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.57
FY2025
5-year range
-$1.32 / -$0.12
FY2021-FY2025
Trend
-9.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $-0.12 to $-0.57 over the past 2 years.
Based on SEC 10-K filings.
-0.57 in FY2025.
Declined from $-0.12 to $-0.57 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 9.9% year-over-year.
- Peak operating cash flow per share was recorded in FY2018.
- Lowest operating cash flow per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.57 | -9.9% |
| FY2024 | -$0.52 | -348.4% |
| FY2023 | -$0.12 | +51.1% |
| FY2022 | -$0.24 | +81.9% |
| FY2021 | -$1.32 | +26.7% |
| FY2020 | -$1.79 | -244.6% |
| FY2019 | -$0.52 | -323.1% |
| FY2018 | $0.23 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026